Press Detail

PRESS RELEASE

Biotest increases earnings after tax by 55%

- New sales record in second quarter 2013

- Capital increase very successfully completed

- Confirmation of Guidance of sales and EBIT growth of 10 - 15% in 2013

Dreieich, 13 August 2013. The Biotest Group achieved record sales in the first six months of 2013 and is still on its projected growth path. In the reporting period the Group generated revenues of EUR 243.3 million compared to EUR 220.2 million in the period of the previous year. This represents an increase of 10.5 %.

Profitability also increased significantly in line with the rise in revenues. Earnings before interest and taxes (EBIT) increased in the reporting period by 13.1 % from EUR 22.9 million to EUR 25.9 million.

The growth in sales was driven primarily by the international markets. Sales in the US increased significantly. The high growth rates in the US were mainly attributable to the market launch of Bivigam(R) in February 2013. The immunoglobulin resulting from our own development, which is used to treat patients with primary humoral immune deficiencies has already generated a sales contribution in the doubledigit million range in the first six months of 2013.

Earnings before taxes (EBT) came in at EUR 23.4 million. EBT is therefore 32.2 % above the comparable amount of EUR 17.7 million in the previous year. Earnings after taxes (EAT) increased significantly from EUR 9.9 million to EUR 15.3 million as a result of only a slight increase in tax expense. Altogether this produced earnings per share of EUR 1.31. This is equivalent to an increase of 56.0 % compared to an earnings per share of EUR 0.84 in the previous year.

In view of the high growth expectations for the global pharmaceutical markets regarding plasma proteins Biotest has decided to expand production capacity called 'Biotest Next Level' investment program. The aim of the project is to double production capacity at the Dreieich location by 2018 and to further strengthen the competitiveness of the Company but also contribute to achieving the target sales figure of EUR 1 billion by the year 2020.

In order to achieve a doubling of capacity it is anticipated that an investment of between EUR 200 and 250 million will be required. At the Annual Shareholders' Meeting of Biotest AG on 8 May 2013 the Management Board announced a capital increase by way of the issue of up to 1,461,909 new preference shares. This measure is an important component for the financing of the largest investment project in the history of the Biotest Group. The capital increase was very successfully completed at the end of June with gross issue proceeds of EUR 76.0 million. The new shares were placed with investors located in Germany and abroad and the share capital was increased by EUR 3.7 million as a result. The issue proceeds will be fully used for the 'Biotest Next Level' expansion of production capacity.

The business performance of the Biotest Group continues to be very positive. For this reason the Management Board reaffirms its target of increasing sales by 10 % to 15 % in the current year. Management expects a similar increase in EBIT.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has about 1.800 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart